Year |
Citation |
Score |
2019 |
McCann JJ, Vasilevskaya IA, Poudel Neupane N, Shafi AA, McNair C, Dylgjeri E, Mandigo AC, Schiewer MJ, Schrecengost RS, Gallagher P, Stanek TJ, McMahon SB, Berman-Booty LD, Ostrander WF, Knudsen KE. USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA repair. Cancer Research. PMID 31740444 DOI: 10.1158/0008-5472.Can-19-1033 |
0.385 |
|
2018 |
Schrecengost RS, Green CL, Zhuang Y, Keller SN, Smith RA, Maines LW, Smith CD. In vitro and in vivo anti-tumor and anti-inflammatory capabilities of the novel GSK3 and CKD9 inhibitor ABC1183. The Journal of Pharmacology and Experimental Therapeutics. PMID 29434052 DOI: 10.1124/Jpet.117.245738 |
0.378 |
|
2018 |
Smith CD, Schrecengost RS, Zhuang Y, Maines LW, Keller SN, Smith RA, Green CL. Abstract B190: Antitumor effects of ABC131, a novel diaminothiazole inhibitor of tubulin Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B190 |
0.376 |
|
2015 |
Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE, Smith CD. Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Molecular Cancer Research : McR. PMID 26271487 DOI: 10.1158/1541-7786.Mcr-14-0626 |
0.44 |
|
2015 |
Jones J, Dean JL, Schrecengost RS, Knudsen K. Abstract 1862: Discerning the role of USP22 in prostate cancer development and progression Cancer Research. 75: 1862-1862. DOI: 10.1158/1538-7445.Am2015-1862 |
0.426 |
|
2015 |
Schrecengost RS, Keller S, Schiewer M, Knudsen K, Smith C. Abstract C94: Dual downregulation of Myc and AR with a sphingosine kinase-2 inhibitor prevents prostate cancer progression Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C94 |
0.48 |
|
2014 |
Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA, Visakorpi T, DeMarzo AM, McMahon SB, Knudsen KE. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Research. 74: 272-86. PMID 24197134 DOI: 10.1158/0008-5472.Can-13-1954 |
0.438 |
|
2014 |
Schrecengost RS, Augello MA, Knudsen KE. Androgen receptor regulation of prostate cancer progression and metastasis Signaling Pathways and Molecular Mediators in Metastasis. 277-309. DOI: 10.1007/978-94-007-2558-4_12 |
0.328 |
|
2013 |
Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Seminars in Oncology. 40: 244-58. PMID 23806491 DOI: 10.1053/J.Seminoncol.2013.04.001 |
0.406 |
|
2013 |
Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH. Breast cancer antiestrogen resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. Plos One. 8: e65678. PMID 23762409 DOI: 10.1371/Journal.Pone.0065678 |
0.795 |
|
2013 |
Wilson AL, Schrecengost RS, Guerrero MS, Thomas KS, Bouton AH. Abstract 3778: Breast Cancer Antiestrogen Resistance 3 (BCAR3) promotes cell motility by regulating actin cytoskeletal and adhesion remodeling in invasive breast cancer cells. Cancer Research. 73: 3778-3778. DOI: 10.1158/1538-7445.Am2013-3778 |
0.813 |
|
2013 |
Schrecengost R, Dean J, Stanek T, Birbe R, Hicks J, Visakorpi T, DeMarzo A, McMahon S, Knudsen K. Abstract 3576: USP22 modulates AR activity to critically regulate prostate cancer progression. Cancer Research. 73: 3576-3576. DOI: 10.1158/1538-7445.Am2013-3576 |
0.511 |
|
2010 |
Schuh NR, Guerrero MS, Schrecengost RS, Bouton AH. BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling. The Journal of Biological Chemistry. 285: 2309-17. PMID 19940159 DOI: 10.1074/Jbc.M109.046631 |
0.604 |
|
2010 |
Schrecengost RS, Wilson AL, Guerrero MS, Bouton AH. Abstract 5135: Breast cancer antiestrogen resistance-3 influences breast cancer cell migration by regulating Rac and Rho GTPase signaling Cancer Research. 70: 5135-5135. DOI: 10.1158/1538-7445.Am10-5135 |
0.808 |
|
2008 |
Deacon DH, Hogan KT, Swanson EM, Chianese-Bullock KA, Denlinger CE, Czarkowski AR, Schrecengost RS, Patterson JW, Teague MW, Slingluff CL. The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines. Bmc Cancer. 8: 360. PMID 19055839 DOI: 10.1186/1471-2407-8-360 |
0.318 |
|
2008 |
Ta HQ, Thomas KS, Schrecengost RS, Bouton AH. A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Research. 68: 8796-804. PMID 18974122 DOI: 10.1158/0008-5472.Can-08-2426 |
0.781 |
|
2007 |
Schrecengost RS, Riggins RB, Thomas KS, Guerrero MS, Bouton AH. Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Research. 67: 6174-82. PMID 17616674 DOI: 10.1158/0008-5472.Can-06-3455 |
0.803 |
|
2007 |
Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer Letters. 256: 1-24. PMID 17475399 DOI: 10.1016/J.Canlet.2007.03.016 |
0.707 |
|
Show low-probability matches. |